The stock of Enanta Pharmaceuticals Inc (ENTA) has seen a 2.77% increase in the past week, with a 41.68% gain in the past month, and a 8.49% flourish in the past quarter. The volatility ratio for the week is 4.94%, and the volatility levels for the past 30 days are at 4.45% for ENTA. The simple moving average for the past 20 days is 14.01% for ENTA’s stock, with a -5.68% simple moving average for the past 200 days.
Is It Worth Investing in Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Right Now?
The 36-month beta value for ENTA is also noteworthy at 0.79. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENTA is 19.86M, and at present, short sellers hold a 13.70% of that float. The average trading volume of ENTA on June 13, 2025 was 199.26K shares.
ENTA) stock’s latest price update
The stock of Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decreased by -6.79 when compared to last closing price of 7.95.Despite this, the company has seen a gain of 2.77% in its stock price over the last five trading days. businesswire.com reported 2025-06-11 that WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved as the only eight-week treatment for adults and pediatric patients three.
Analysts’ Opinion of ENTA
Many brokerage firms have already submitted their reports for ENTA stocks, with JP Morgan repeating the rating for ENTA by listing it as a “Underweight.” The predicted price for ENTA in the upcoming period, according to JP Morgan is $14 based on the research report published on August 09, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ENTA reach a price target of $18, previously predicting the price at $49. The rating they have provided for ENTA stocks is “Hold” according to the report published on August 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to ENTA, setting the target price at $56 in the report published on December 09th of the previous year.
ENTA Trading at 29.13% from the 50-Day Moving Average
After a stumble in the market that brought ENTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTA starting from Luly Jay R., who purchase 45,000 shares at the price of $5.69 back on Feb 12 ’25. After this action, Luly Jay R. now owns 846,638 shares of Enanta Pharmaceuticals Inc, valued at $256,050 using the latest closing price.
Kieffer Tara Lynn, the Chief Product Strategy Officer of Enanta Pharmaceuticals Inc, sale 2,283 shares at $8.06 during a trade that took place back on Dec 06 ’24, which means that Kieffer Tara Lynn is holding 29,305 shares at $18,401 based on the most recent closing price.
Stock Fundamentals for ENTA
Current profitability levels for the company are sitting at:
- -1.58 for the present operating margin
- 1.0 for the gross margin
The net margin for Enanta Pharmaceuticals Inc stands at -1.5. The total capital return value is set at -0.37. Equity return is now at value -74.26, with -26.18 for asset returns.
Based on Enanta Pharmaceuticals Inc (ENTA), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -0.94. The debt to equity ratio resting at 0.63. The interest coverage ratio of the stock is -11.86.
Currently, EBITDA for the company is -104.51 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.43. The receivables turnover for the company is 9.49for trailing twelve months and the total asset turnover is 0.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.29.
Conclusion
In summary, Enanta Pharmaceuticals Inc (ENTA) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
